Tc 99m P215
Alternative Names: P215Latest Information Update: 11 Sep 2006
At a glance
- Originator Bayer Schering Pharma
- Class Organotechnetium compounds; Peptide diagnostics; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Technetium compounds
- Mechanism of Action Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis
Most Recent Events
- 11 Sep 2006 Discontinued - Phase-II for Atherosclerosis diagnosis in USA (unspecified route)
- 09 Oct 2001 No development reported - Phase-II for Atherosclerosis diagnosis in USA (unspecified route)
- 16 Nov 1999 Diatide has been acquired by Schering AG